Immunotherapy is making a difference in patients with triple negative breast cancer (TNBC). The Keynote-522 trial showed pembrolizumab improves response rate and prolongs disease-free survival. Other combinations in clinical trials look promising.

Stay informed about cutting-edge developments in cancer treatment by subscribing. Like, share, and don’t forget to like and comment below with your thoughts or questions!

Chapters
00:00 Introduction

#Cancer #cancertreatment #breastcancer

About us:

Cancer Treatment Updates is a deep-dive podcast focusing on cancer biology, research and treatment. It features topics including molecular classification of cancer and its impact on prognosis, predictive markers, chemotherapy, endocrine therapy, targeted therapy, immunotherapy, surgery, radiation therapy, risk assessment, survivorship and much more.

Dr. Francisco Javier Esteva is a medical oncologist based in New York City. He currently serves as Chief of Hematology and Medical Oncology at Lenox Hill Hospital, an academic institution of Northwell Health. Opinions are his own, and not reflective of the opinions or views of his employer.

Learn more: www.cancertreatmentupdates.com

Follow Dr. Esteva:
Instagram [ Ссылка ]
Facebook [ Ссылка ]
Twitter (X) [ Ссылка ]
TikTok [ Ссылка ]
LinkedIn [ Ссылка ]
Google Scholar: [ Ссылка ]
YouTube [ Ссылка ]

Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this visual podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. Please review our Terms of Use: [ Ссылка ].

свернуть